Important Therapeutic Targets in Chronic Myelogenous Leukemia - Kantarjian, Hagop M.; Giles, Francis; Quintás-Cardama, Alfonso; Cortes, Jorge (Clinical cancer research, 2007)
Keywords: Antineoplastic agents; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; BCR-ABL; Benzamides; Biological and medical sciences; chronic myeloid leukemia; dasatinib; Fusion Proteins, bcr-abl; Hematologic and hematopoietic diseases; Humans; imatinib; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; nilotinib; Pharmacology. Drug treatments; Piperazines - pharmacology; Piperazines - therapeutic use; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - antagonists & inhibitors; Protein-Tyrosine Kinases - metabolism; Pyrimidines - pharmacology; Pyrimidines - therapeutic use; Myeloproliferative syndrome; Malignant hemopathy; Targeting; Targeted therapy; Chronic myelocytic leukemia